Medpace Holdings, Inc. (MEDP) Return on Invested Capital (ROIC): 67.94%
Is Medpace Holdings, Inc.’s return on invested capital (ROIC) high or low?
Medpace Holdings, Inc.'s return on invested capital (ROIC) of 67.94% is 89% above its 5-year average of 35.95%, near the high end of its 5-year range (15.16%–67.94%).
As of Wednesday, June 17, 2026. 29.19% above its 12-month average of 52.59%.
MEDP Return on Invested Capital (ROIC) Chart
MEDP Average Return on Invested Capital (ROIC) Chart
MEDP Current vs Average Return on Invested Capital (ROIC) Chart
MEDP Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
67.94%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
52.59%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
46.08%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
35.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
22.88%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+29.19%
CURRENT VS 3Y AVG
+47.44%
CURRENT VS 5Y AVG
+88.98%
CURRENT VS 10Y AVG
+196.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 67.94% | 52.59% | 46.08% | 35.95% |
| Solventum Corporation (SOLV)vs › | $12.91B | 17.76% | 12.30% | 11.68% | 9.70% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 3.98% | 4.09% | 3.90% | 4.29% |
| DaVita Inc. (DVA)vs › | $13.52B | 10.58% | 10.99% | 9.48% | 9.31% |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 9.94% | 9.96% | 10.13% | 11.66% |
| Revvity, Inc. (RVTY)vs › | $10.91B | 2.82% | 2.97% | 3.42% | 5.50% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -24.28% | -15.13% | -6.38% | -2.73% |
| Baxter International Inc. (BAX)vs › | $10.19B | -1.79% | -0.86% | -2.61% | 0.30% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 7.35% | 8.59% | 9.78% | 13.56% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | 8.36% | 4.65% | 6.09% | 6.66% |
Capital Efficiency
ROIC
67.9%
ROE
77.0%
Medpace Holdings, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Medpace Holdings, Inc. (MEDP)?
- The return on invested capital (ROIC) for MEDP stock is 67.94%.
- Is Medpace Holdings, Inc.'s return on invested capital (ROIC) high or low?
- Medpace Holdings, Inc.'s return on invested capital (ROIC) of 67.94% is 89% above its 5-year average of 35.95%, near the high end of its 5-year range (15.16%–67.94%).
- What is the TTM average return on invested capital (ROIC) for Medpace Holdings, Inc. (MEDP)?
- The TTM average return on invested capital (ROIC) for MEDP stock is 52.59%.
- What is the 3Y average return on invested capital (ROIC) for Medpace Holdings, Inc. (MEDP)?
- The 3Y average return on invested capital (ROIC) for MEDP stock is 46.08%.
- What is the 5Y average return on invested capital (ROIC) for Medpace Holdings, Inc. (MEDP)?
- The 5Y average return on invested capital (ROIC) for MEDP stock is 35.95%.
- What is the 10Y average return on invested capital (ROIC) for Medpace Holdings, Inc. (MEDP)?
- The 10Y average return on invested capital (ROIC) for MEDP stock is 22.88%.
Medpace Holdings, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 67.94% |
| 2024-12-31 | 37.24% |
| 2023-12-31 | 38.78% |
| 2022-12-31 | 40.36% |
| 2021-12-31 | 16.23% |
| 2020-12-31 | 15.16% |
| 2019-12-31 | 12.80% |
| 2018-12-31 | 11.07% |
| 2017-12-31 | 5.75% |
| 2016-12-31 | 3.90% |
| 2015-12-31 | 2.42% |
| 2014-12-31 | 1.98% |
| 2013-12-31 | 0.00% |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle